We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gene Editing Reduces Symptoms of Parasite Infection in Models

By LabMedica International staff writers
Posted on 29 Jan 2019
Print article
Image: Researchers \"knocked out\" the omega-1 ribonuclease protein using CRISPR/Cas9 and found that it greatly reduced the impact of schistosomiasis (Photo courtesy of George Washington University).
Image: Researchers \"knocked out\" the omega-1 ribonuclease protein using CRISPR/Cas9 and found that it greatly reduced the impact of schistosomiasis (Photo courtesy of George Washington University).
Tropical disease researchers used the CRISPR/Cas9 genome-editing tool to interfere with the ability of certain parasitic worms to invade and reproduce in rodent model systems.

CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system from Streptococcus pyogenes is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.

Investigators at George Washington University (Washington, DC, USA) employed CRISPR/Cas9 to modify the genomes of the parasites Schistosoma mansoni and Opisthorchis viverrini. S. mansoni causes schistosomiasis, in which freshwater worms enter the body by burrowing through the skin. The parasites then move through the bloodstream to lodge primarily in the liver where they lay eggs and reproduce. O. viverrini is a river fluke infection transmitted through traditional Southeast Asian cuisines. Infection by this parasite has been identified as a major risk factor for the development of usually fatal bile duct cancer (cholangiocarcinoma).

Each of these parasites produces and secretes characteristic proteins during the reproductive process that cause damage to surrounding host tissues. In the case of S. manosi, one such protein is the enzyme omega-1 ribonuclease, while O. viverrini parasites produce the growth factor, liver fluke granulin (Ov-grn-1).

In two papers published in the January 15, 2019, online edition of the journal eLife the investigators described how using CRISPR/Cas9 to eliminate the gene for omega-1 ribonuclease in S. mansoni eggs and the gene for Ov-grn-1 in O. viverrini affected infection by these organisms in rodent models.

Gene-edited Schistosoma eggs failed to polarize Th2 cytokine responses in macrophage/T-cell co-cultures, while the volume of pulmonary granulomas surrounding omega1-mutated eggs following tail-vein injection into mice was vastly reduced. In O. viverrini gene editing resulted in rapid depletion of Ov-grn-1 transcripts and the encoded Ov-grn-1 protein. Gene-edited parasites colonized the biliary tract of hamsters and developed into adult flukes, but the infection resulted in reduced pathology as evidenced by attenuated biliary hyperplasia and fibrosis.

"The genes we "knocked out" using CRISPR/Cas9 resulted in markedly diminished symptoms of infection in our animal models," said one of the senior authors, Dr. Paul Brindley, professor of microbiology, immunology, and tropical medicine at George Washington University. "Our research also showed that this revolutionary new biomedical procedure -- CRISPR/Cas9 -- can be adapted to study helminth parasites, which are a major public health problem in tropical climates."

"These neglected tropical diseases affect more than a quarter of a billion people primarily living in Southeast Asia, sub-Saharan Africa, and Latin America," said Dr. Brindley. "CRISPR/Cas9 is a tool that may be used to limit the impact of these infections. As we work to better understand how these parasites invade and damage our bodies through this new technology, we will find new ideas for treatment and disease control."

Related Links:
George Washington University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more